Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

医学 内科学 转移性尿路上皮癌 肿瘤科 临床终点 实体瘤疗效评价标准 尿路上皮癌 临床研究阶段 顺铂 化疗 临床试验 癌症 膀胱癌
作者
Evan Y. Yu,Daniel P. Petrylak,Peter H. O’Donnell,Jae‐Lyun Lee,Michiel S. van der Heijden,Yohann Loriot,Mark N. Stein,Andrea Necchi,Takahiro Kojima,Michael R. Harrison,Se Hoon Park,David I. Quinn,Elisabeth I. Heath,Jonathan E. Rosenberg,Joyce Steinberg,Shang-Ying Liang,Janet Trowbridge,Mary S. Campbell,Bradley A. McGregor,Arjun Vasant Balar
出处
期刊:Lancet Oncology [Elsevier]
卷期号:22 (6): 872-882 被引量:164
标识
DOI:10.1016/s1470-2045(21)00094-2
摘要

Summary

Background

Locally advanced or metastatic urothelial carcinoma is generally incurable and has scarce treatment options, especially for cisplatin-ineligible patients previously treated with PD-1 or PD-L1 therapy. Enfortumab vedotin is an antibody–drug conjugate directed at Nectin-4, a protein highly expressed in urothelial carcinoma. We aimed to evaluate the efficacy and safety of enfortumab vedotin in the post-immunotherapy setting in cisplatin-ineligible patients.

Methods

EV-201 is a multicentre, single-arm, phase 2 study of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma previously treated with PD-1 or PD-L1 inhibitors. Cohort 2 included adults (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status score of 2 or less who were considered ineligible for cisplatin at enrolment and who had not received platinum-containing chemotherapy in the locally advanced or metastatic setting. Enfortumab vedotin was given intravenously at a dose of 1·25 mg/kg on days 1, 8, and 15 of every 28-day cycle. The primary endpoint was confirmed objective response rate per Response Evaluation Criteria in Solid Tumours version 1.1 assessed by blinded independent central review. Efficacy and safety were analysed in all patients who received at least one dose of enfortumab vedotin. EV-201 is an ongoing study and the primary analysis is complete. This study is registered with Clinicaltrials.gov, NCT03219333.

Findings

Between Oct 8, 2017, and Feb 11, 2020, 91 patients were enrolled at 40 sites globally, of whom 89 received treatment. Median follow-up was 13·4 months (IQR 11·3–18·9). At data cutoff (Sept 8, 2020), the confirmed objective response rate was 52% (46 of 89 patients; 95% CI 41–62), with 18 (20%) of 89 patients achieving a complete response and 28 (31%) achieving a partial response. 49 (55%) of 89 patients had grade 3 or worse treatment-related adverse events. The most common grade 3 or 4 treatment-related adverse events were neutropenia (eight [9%] patients), maculopapular rash (seven [8%] patients), and fatigue (six [7%] patients). Treatment-related serious adverse events occurred in 15 (17%) patients. Three (3%) patients died due to acute kidney injury, metabolic acidosis, and multiple organ dysfunction syndrome (one [1%] each) within 30 days of first dose and these deaths were considered by the investigator to be related to treatment; a fourth death from pneumonitis occurred more than 30 days after the last dose and was also considered to be related to treatment.

Interpretation

Treatment with enfortumab vedotin was tolerable and confirmed responses were seen in 52% of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma who were previously treated with PD-1 or PD-L1 inhibitors. These patients have few treatment options, and enfortumab vedotin could be a promising new therapy for a patient population with a high unmet need.

Funding

Astellas Pharma Global Development and Seagen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
犹豫小海豚完成签到,获得积分10
3秒前
是容许鸭完成签到,获得积分10
5秒前
223311完成签到,获得积分10
6秒前
薄荷小姐完成签到 ,获得积分10
6秒前
慕青应助兆丰采纳,获得10
6秒前
xcwy完成签到,获得积分10
7秒前
yellow完成签到 ,获得积分10
7秒前
lulyt完成签到 ,获得积分10
7秒前
科研通AI2S应助zhoushuai1a采纳,获得10
9秒前
英俊的铭应助Min采纳,获得10
12秒前
Loooong完成签到,获得积分0
16秒前
合适冰棍完成签到 ,获得积分10
18秒前
vikey完成签到 ,获得积分10
19秒前
21秒前
小亮哈哈完成签到,获得积分10
22秒前
A晨完成签到 ,获得积分10
23秒前
00完成签到 ,获得积分10
24秒前
Accepted完成签到,获得积分10
25秒前
why完成签到,获得积分10
25秒前
qaplay完成签到 ,获得积分0
25秒前
Min发布了新的文献求助10
26秒前
kongxiangjiu完成签到,获得积分0
26秒前
糊涂的尔蝶完成签到,获得积分10
30秒前
yoyocici1505完成签到,获得积分10
30秒前
开心便当完成签到,获得积分10
31秒前
自觉画笔完成签到 ,获得积分10
32秒前
合适的寄灵完成签到 ,获得积分10
32秒前
lzc完成签到 ,获得积分10
32秒前
Min完成签到,获得积分10
32秒前
Lenard Guma完成签到 ,获得积分10
35秒前
fyjlfy完成签到 ,获得积分10
36秒前
wei完成签到,获得积分10
36秒前
Ava应助wodetaiyangLLL采纳,获得10
36秒前
罗良干完成签到 ,获得积分10
37秒前
派大星完成签到,获得积分10
37秒前
37秒前
木木完成签到 ,获得积分10
38秒前
爱笑半雪完成签到,获得积分10
40秒前
beyond_xdy完成签到 ,获得积分10
40秒前
红叶完成签到,获得积分10
40秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Subjective Well-Being and Life Satisfaction (第二版) 1000
The Data Economy: Tools and Applications 1000
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufen 700
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
Acute Care Physical Therapy 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3095257
求助须知:如何正确求助?哪些是违规求助? 2747157
关于积分的说明 7593132
捐赠科研通 2398779
什么是DOI,文献DOI怎么找? 1272689
科研通“疑难数据库(出版商)”最低求助积分说明 615427
版权声明 598931